Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS‐II Nutrition Cohort

Citations Over TimeTop 19% of 2008 papers

Abstract

Abstract BACKGROUND The HDL‐associated enzyme paraoxonase 1 acts to decrease oxidative stress, which is thought to contribute to cancer development. PON1 , which encodes paraoxonase 1, has two common, nonsynonymous SNPs that alter the activity of this enzyme and may influence cancer risk. METHODS We investigated the association the nonsynonymous SNPs, Q192R and L55M, with prostate cancer risk in a nested case–control analysis of 1,268 cases and 1,268 matched controls from the American Cancer Society CPS‐II Nutrition Cohort. RESULTS For both the Q192R and L55MSNPs, the presence of the variant allele was associated with an increased risk of aggressive prostate cancer that approached statistical significance. The genotype combination that included one variant allele from both SNPs (QR/LM) was associated with an increased risk of more than twofold (OR = 2.18, 95% CI: 1.31, 3.64). CONCLUSIONS These findings suggest that the Q129R and the L55M SNP may be associated with increased risk of aggressive prostate, perhaps through attenuation of paraoxonase l activity. Prostate 68:1336–1340, 2008. © 2008 Wiley‐Liss, Inc.

Related Papers

• → Modulation of paraoxonase (PON1) activity(2004)482 cited
• → Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes(2005)156 cited
• → Activity of paraoxonase 1 and lipid profile in healthy children(2007)32 cited
• Original Contribution SERUM PARAOXONASE AND ARYLESTERASE ACTIVITY OF PON1 IN ACUTE CORONARY SYNDROME(2013)
• Two Decades of Paraoxonase 1 (PON1) and Atherosclerosis(2010)